PsychoGenics Inc., of Tarrytown, N.Y., named Rusiko Bourtchouladze vice president of cognition and discovery research.
Quantum Genomics Corp., of Jersey City, N.J., appointed Jean-Pierre Riffaud as head of preclinical development.
QuatRx Pharmaceuticals, of Ann Arbor, Mich., appointed Rochelle Hanley as chief medical officer.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., named Peter Powchik senior vice president of clinical development.
Replidyne Inc., of Louisville, Colo., appointed J.C. Lee vice president of manufacturing, and Sabrina Oei director of investor and public relations.
Santhera Pharmaceuticals, of Liestal, Switzerland, appointed MJ Roach vice president of marketing and sales.
Sc Capital Partners, of Philadelphia, named Edward Erickson a venture partner.
Sigma-Aldrich Corp., of St. Louis, elected Steven Paul a director.
SkyePharma plc, of London, appointed Peter Grant finance director.
Somaxon Pharmaceuticals Inc., of San Diego, appointed Brian Dorsey vice president of manufacturing and program management.
Starpharma Holdings Ltd., of Melbourne, Australia, appointed Richard Hazleton a non-executive director.
SVB Financial Group, of Menlo Park, Calif., named Jon Norris the managing director of SVB Capital Private Equity Group.
Symphogen, of Copenhagen, Denmark, said Christian Meyer was appointed vice president of clinical development.